Collectively, these results strongly suggest that downregulation of FILIP1L is clinically relevant in LUAD and warrant further efforts to evaluate pharmacologic regimens that either directly or indirectly restore FILIP1L-mediated gene regulation for the treatment of these neoplasms. This evidence concerns the gene FILIP1L and neoplasm.